- Home
- PMTS vs TSHA Comparison
PMTS vs TSHA Comparison
Compare PMTS & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMTS
- TSHA
- Stock Information
- Founded
- PMTS 2007
- TSHA 2019
- Country
- PMTS United States
- TSHA United States
- Employees
- PMTS N/A
- TSHA N/A
- Industry
- PMTS Finance Companies
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- PMTS Finance
- TSHA Health Care
- Exchange
- PMTS Nasdaq
- TSHA Nasdaq
- Market Cap
- PMTS 316.9M
- TSHA 334.1M
- IPO Year
- PMTS 2015
- TSHA 2020
- Fundamental
- Price
- PMTS $28.47
- TSHA $1.74
- Analyst Decision
- PMTS Strong Buy
- TSHA Strong Buy
- Analyst Count
- PMTS 5
- TSHA 8
- Target Price
- PMTS $34.40
- TSHA $6.63
- AVG Volume (30 Days)
- PMTS 36.3K
- TSHA 1.5M
- Earning Date
- PMTS 03-04-2025
- TSHA 02-26-2025
- Dividend Yield
- PMTS N/A
- TSHA N/A
- EPS Growth
- PMTS N/A
- TSHA N/A
- EPS
- PMTS 1.64
- TSHA N/A
- Revenue
- PMTS $480,601,000.00
- TSHA $8,333,000.00
- Revenue This Year
- PMTS $8.62
- TSHA N/A
- Revenue Next Year
- PMTS $7.15
- TSHA N/A
- P/E Ratio
- PMTS $17.33
- TSHA N/A
- Revenue Growth
- PMTS 8.11
- TSHA N/A
- 52 Week Low
- PMTS $15.21
- TSHA $1.19
- 52 Week High
- PMTS $35.19
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- PMTS 43.51
- TSHA 54.79
- Support Level
- PMTS $27.57
- TSHA $1.69
- Resistance Level
- PMTS $29.83
- TSHA $1.82
- Average True Range (ATR)
- PMTS 1.96
- TSHA 0.10
- MACD
- PMTS -0.19
- TSHA 0.01
- Stochastic Oscillator
- PMTS 18.65
- TSHA 68.00
About PMTS CPI Card Group Inc.
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.